United Therapeutics stock is booming

The biotech company is developing multiple treatments for pulmonary arterial hypertension, which is a form of high blood pressure in the lungs, as well as treatments for other diseases. Its drug Tyvaso should benefit from a regulatory approval delay for a competing drug, leaving UTHR without direct competition to hinder its business development efforts.

Financially, the company’s second-quarter performance showed revenue growth of nearly 20% and earnings per share growth of 12%. The UTHR pipeline is also promising. Analysts suggest that the commercialization of new therapies could generate profits of 50% or more in the next few years.

No wonder UTHR shares are up 64% this year – and could rise more. MAPsignals data shows how Big Money investors are betting heavily on the anticipated picture of stocks.

United Therapeutics under heavy accumulation

Institutional volumes reveal a lot. Recently, UTHR has enjoyed strong investor demand, which we believe is institutional support.

Each green bar signals unusually high volumes in UTHR stock. These reflect our proprietary entry signal pushing the stock higher:

A lot of health care names are piling up now. But there is a strong fundamental story going on with United Therapeutics.

Fundamental Analysis of United Therapeutics

Institutional support and a sound fundamental background make this company worth investigating. As you can see, UTHR has seen strong sales and earnings growth:

Source: FactSet

EPS is also expected to grow this year by +14.8%.

Now it makes sense why the stock has reached new highs. UTHR has a track record of strong financial performance.

Combining great fundamentals with our proprietary software has found some big winning stocks over the long term.

United Therapeutics has been a top stock on MAPsignals for years. That means the stock has unusual buying pressure and rising fundamentals. We have a ranking process that features such stocks weekly.

It has made the rarity Top 20 several times in the past year. The blue bars below show when UTHR was a top pick… sending the stock up:

Tracking unusual volumes reveals the strength of cash flows.

This is a trait that most outliers exhibit…the best of the best. High demand for money drives stocks up.

United Therapeutics Price Prediction

The UTHR rally is not new at all. Buying stocks with Big Money means paying attention. Given its historical share price gains and strong fundamentals, this stock could be worth a place in a diversified portfolio.

The story continues

Disclosure: The author holds no position in UTHR at the time of publication.

If you are a Registered Investment Advisor (RIA) or a serious investor taking your investing to the next level, learn more about the MAPsignals process here.

This article was originally posted on FX Empire

More from FXEMPIRE: